Irinotecan hydrochloride hydrate

Irinotecan hydrochloride hydrate is a hydrate that is the trihydrate form of irinotecan hydrochloride. Onivyde is used in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, that is ~1000 times more active. Among its listed roles, it functions as a EC 5.99.1.2 (DNA topoisomerase) inhibitor, an antineoplastic agent, an apoptosis inducer and a prodrug. It includes a irinotecan hydrochloride (anhydrous). It is grouped under the following drug class(es): Topoisomerase inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Irinotecan Hydrochloride Trihydrate, Camptosar and Irinotecan HCL Trihydrate. Its PubChem CID is 60837.

CAS No 136572-09-3
Molecular Formula C33H45ClN4O9
Molecular Weight 677.2 g/mol
Synonyms [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;trihydrate;hydrochloride

Zoho Contact Form

"*" indicates required fields

I am a*
This field is for validation purposes and should be left unchanged.

Frequently Asked Questions